 LONDON ACCESSWIRE March 31, 2020 Midatech Pharma PLC MTPH.LMTP, an RD; biotechnology company focused on delivering innovative oncology and rare disease products to patients announces that, in view of prevailing conditions in the capital markets and the prospects for raising additional funds and partnering of assets, the Board of Midatech is in the process of implementing a strategic review of its operations. The Company believes the remaining costs to complete the Phase III clinical programme of MTD201 octreotide sustained release and manufacturing scale-up at its Bilbao facility are of the order of 30 million. The Board has concluded, in the context of its current cash runway, that the Company is unlikely to conclude a license transaction or raise sufficient funds to continue the required remaining investment in MTD201 on a timely basis. 